-
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal
Tuesday, May 17, 2022 - 12:08pm | 271Read More...Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities. The Teva Pharmaceutical Industries Analyst: Jason Gerberry upgraded the rating for Teva...
-
Opiant Pharma Advances OPNT003 PK Study With First Patient Dosing
Tuesday, February 9, 2021 - 12:30pm | 221Read More...Opiant Pharmaceuticals Inc (NASDAQ: OPNT) doses the first patient in a confirmatory pharmacokinetic (PK) study evaluating OPNT003 (nasal nalmefene) for opioid overdose treatment. Results from the study are anticipated in June 2021. The open-label, randomized, crossover study...
-
White House To Loosen Controls On Heroin Addiction Treatment
Wednesday, July 6, 2016 - 9:00am | 308Read More...The Wall Street Journal recently reported President Obama’s administration will loosen its strict controls on a medication called buprenorphine, which is used to treat addiction to heroin and other opioid-based drugs. The Department of Health and Human Services up until now only allowed...
